Evidence map›Paper›PMID 25836633›Full record

ArticlePLoS pathogens2015

Hantaan virus infection induces both Th1 and ThGranzyme B+ cell immune responses that associated with viral control and clinical outcome in humans.

Ying Ma, Bin Yuan, Ran Zhuang, Yusi Zhang, Bei Liu, Chunmei Zhang, Yun Zhang, Haitao Yu, Jing Yi, Angang Yang and 1 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 60 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. In Vitro Evaluation of Bunyavirus T Cell Immunity.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Correlation analysis of CD8Frontiers in pediatrics · 2023
    Article
  16. Increased blood CD226Annals of medicine · 2023
    Article
  17. Article
  18. Increased CD4Viruses · 2022
    Article
  19. Anti-platelet factor 4/heparin antibodies in patients with Hantaan virus infection.Research and practice in thrombosis and haemostasis · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Ying MaDepartment of Immunology, the Fourth Military Medical University, Xi'an, China.
Bin YuanInstitute of Orthopaedics of Xijing Hospital, the Fourth Military Medical University, Xi'an, China.
Ran ZhuangDepartment of Immunology, the Fourth Military Medical University, Xi'an, China.
Yusi ZhangDepartment of Immunology, the Fourth Military Medical University, Xi'an, China.
Bei LiuDepartment of Immunology, the Fourth Military Medical University, Xi'an, China.
Chunmei ZhangDepartment of Immunology, the Fourth Military Medical University, Xi'an, China.
Yun ZhangDepartment of Immunology, the Fourth Military Medical University, Xi'an, China.
Haitao YuDepartment of Infectious Diseases of Tangdu Hospital, the Fourth Military Medical University, Xi'an, China.
Jing YiDepartment of Immunology, the Fourth Military Medical University, Xi'an, China.
Angang YangDepartment of Immunology, the Fourth Military Medical University, Xi'an, China.
Boquan JinDepartment of Immunology, the Fourth Military Medical University, Xi'an, China.
Air Force Medical University · CNXijing Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hantaviruses infection causing severe emerging diseases with high mortality rates in humans has become public health concern globally. The potential roles of CD4(+)T cells in viral control have been extensively studied. However, the contribution of CD4(+)T cells to the host response against Hantaan virus (HTNV) infection remains unclear. Here, based on the T-cell epitopes mapped on HTNV glycoprotein, we studied the effects and characteristics of CD4(+)T-cell responses in determining the outcome of hemorrhagic fever with renal syndrome. A total of 79 novel 15-mer T-cell epitopes on the HTNV glycoprotein were identified, among which 20 peptides were dominant target epitopes. Importantly, we showed the presence of both effective Th1 responses with polyfunctional cytokine secretion and ThGranzyme B(+) cell responses with cytotoxic mediators production against HTNV infection. The HTNV glycoprotein-specific CD4(+)T-cell responses inversely correlated with the plasma HTNV RNA load in patients. Individuals with milder disease outcomes showed broader epitopes targeted and stronger CD4(+)T-cell responses against HTNV glycoproteins compared with more severe patients. The CD4(+)T cells characterized by broader antigenic repertoire, stronger polyfunctional responses, better expansion capacity and highly differentiated effector memory phenotype(CD27-CD28-CCR7-CD45RA-CD127(hi)) would elicit greater defense against HTNV infection and lead to much milder outcome of the disease. The host defense mediated by CD4(+)T cells may through the inducing antiviral condition of the host cells and cytotoxic effect of ThGranzyme B+ cells. Thus, these findings highlight the efforts of CD4(+)T-cell immunity to HTNV control and provide crucial information to better understand the immune defense against HTNV infection.

Indexed as

AdultCD8-Positive T-LymphocytesEnzyme-Linked Immunosorbent AssayEpitopes, T-LymphocyteFemaleFlow CytometryGlycoproteinsGranzymesHantaan virusHemorrhagic Fever with Renal SyndromeHumansLymphocyte ActivationMolecular Sequence DataPolymerase Chain ReactionRNA, ViralTh1 CellsEpitopes, T-LymphocyteGlycoproteinsGranzymesRNA, ViralViral Proteins

Identifiers

PMID25836633
PMCPMC4383613
OpenAlexW2054995049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.